Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Placebo-Controlled Study of LY3471851 (NKTR-358) in Adults with Systemic Lupus Erythematosus
2019-003323-38Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing LY3471851 Q2W with Placebo (2 arms). Primary endpoint: SLEDAI-4 response at Week 24. Started Jul 2020; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2019-003323-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003323-38.